These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 16677415

  • 1. Cancer and kinases: reports from the front line.
    Burley SK.
    Genome Biol; 2006; 7(4):314. PubMed ID: 16677415
    [Abstract] [Full Text] [Related]

  • 2. Commentary: Novel therapies for cancer: why dirty might be better.
    Fojo T.
    Oncologist; 2008 Mar; 13(3):277-83. PubMed ID: 18378537
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Optimal front-line ALK (anaplastic lymphoma kinase) directed therapy.
    Gadgeel SM.
    Lung Cancer; 2017 Jul; 109():147-148. PubMed ID: 28365051
    [No Abstract] [Full Text] [Related]

  • 7. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
    Yamaoka T, Kusumoto S, Ando K, Ohba M, Ohmori T.
    Int J Mol Sci; 2018 Nov 06; 19(11):. PubMed ID: 30404198
    [Abstract] [Full Text] [Related]

  • 8. Targeting receptor tyrosine kinases in solid tumors.
    Zhang J, Hochwald SN.
    Surg Oncol Clin N Am; 2013 Oct 06; 22(4):685-703. PubMed ID: 24012395
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Tumour-agnostic drugs and future cancer treatment.
    Børset M.
    Tidsskr Nor Laegeforen; 2019 Mar 12; 139(5):. PubMed ID: 30872821
    [No Abstract] [Full Text] [Related]

  • 13. Heritable resistance to tyrosine kinase inhibitors.
    Ong ST.
    Clin Adv Hematol Oncol; 2014 Jul 12; 12(7):454-7. PubMed ID: 25322326
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Tyrosine kinases as targets in cancer therapy - successes and failures.
    Traxler P.
    Expert Opin Ther Targets; 2003 Apr 12; 7(2):215-34. PubMed ID: 12667099
    [Abstract] [Full Text] [Related]

  • 16. [Tyrosine kinases as targets of cancer therapy: from disbelief to Lazarus responses].
    Joensuu H.
    Duodecim; 2012 Apr 12; 128(21):2261-8. PubMed ID: 23210289
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC, Seoane S, Ocaña A, Pandiella A.
    Clin Cancer Res; 2011 Sep 01; 17(17):5546-52. PubMed ID: 21670084
    [Abstract] [Full Text] [Related]

  • 18. Assessing the potential role of next generation tyrosine kinase inhibitors in the treatment of cancers with acquired kinase domain mutations.
    Thirumal Raj A, Patil S, Ranadheer R, Chandini R.
    Oral Oncol; 2017 Oct 01; 73():172. PubMed ID: 28923250
    [No Abstract] [Full Text] [Related]

  • 19. Bad patients meet good drugs.
    Lacal JC.
    Clin Transl Oncol; 2006 Apr 01; 8(4):225-7. PubMed ID: 16648096
    [No Abstract] [Full Text] [Related]

  • 20. Targeted therapy for solid tumors: current status.
    Zureikat AH, McKee MD.
    Surg Oncol Clin N Am; 2008 Apr 01; 17(2):279-301, vii-viii. PubMed ID: 18375353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.